COVID-19 testing problems started early, U.S. still playing from behind
NEW YORK – Four months since the first COVID-19 case was reported in the U.S., the demand for testing for the SARS-CoV-2 virus still far outpaces the supply, even as test developers scramble to increase their testing capacity and new types of tests make their way into the market.
On Jan. 31, a little more than two weeks after COVID-19 hit the U.S., the Trump administration declared a public health emergency. Four days later, the FDA gave a Centers for Disease Control and Prevention test an emergency use authorization.
We fell behind the curve from the beginning,” said Harry Glorikian a general partner at New Ventures Funds, a venture capital firm that invests in therapeutics, precision medicine, diagnostics, and technology companies
To read the full article click on the link below: